Edition:
United Kingdom

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

56.90USD
15 Dec 2017
Change (% chg)

$1.85 (+3.36%)
Prev Close
$55.05
Open
$55.13
Day's High
$57.42
Day's Low
$55.13
Volume
2,010,509
Avg. Vol
624,399
52-wk High
$57.79
52-wk Low
$11.42

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $3,878.49
Shares Outstanding(Mil.): 156.33
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement

* NEKTAR THERAPEUTICS - ‍ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007​ Source text: (http://bit.ly/2BsgSdG) Further company coverage:

15 Dec 2017

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement

* NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018

12 Dec 2017

BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs

24 Nov 2017

BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​ Source text (http://bit.ly/2zxBcXv) Further company coverage:

10 Nov 2017

BRIEF-Nektar Therapeutics reports Q3 earnings per share $0.39

* Nektar Therapeutics reports financial results for the third quarter of 2017

07 Nov 2017

BRIEF-Nektar Therapeutics presents preclinical data on NKTR-358

* Presents preclinical data on NKTR-358, a first-in-class regulatory T Cell stimulator, at 2017 American College of Rheumatology Annual Meeting Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Nektar Therapeutics initiates propel clinical study

* Nektar Therapeutics initiates propel clinical study to evaluate combination of NKTR-214, a CD122-biased agonist, with tecentriq (atezolizumab) or keytruda (pembrolizumab) Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement

* Nektar Therapeutics - Co, Eli Lilly got notice of early termination of waiting period related to license agreement to co-develop NKTR-358 - SEC filing Source text:[http://bit.ly/2wFqKyD] Further company coverage:

25 Aug 2017

BRIEF-Nektar Therapeutics Q2 loss per share $0.39

* Nektar therapeutics reports financial results for the second quarter of 2017

08 Aug 2017

BRIEF-Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358

* Lilly and Nektar Therapeutics announce alliance to develop and commercialize NKTR-358, an autoimmune therapy

24 Jul 2017

Competitors

Earnings vs. Estimates